News headlines about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.757543991838 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC (finance.yahoo.com)
- EPS for AVEO Pharmaceuticals, Inc. (AVEO) Expected At $-0.02 – Flаtlаnd Nеws (flatlandnews.com)
- Comprehensive Stock Analysis – AVEO Pharmaceuticals Inc (NASDAQ: AVEO) – Alpha Beta Stock (alphabetastock.com)
- AVEO Pharmaceuticals, Inc. (AVEO) : Stock in the Analysts Spotlight – Wall Street Morning (wallstreetmorning.com)
- Hot Stock’s Highlights: AVEO Pharmaceuticals Inc (NASDAQ: AVEO) – Alpha Beta Stock (alphabetastock.com)
Shares of AVEO stock traded up $0.09 on Wednesday, reaching $3.00. The company’s stock had a trading volume of 2,211,705 shares, compared to its average volume of 1,716,711. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of -0.45. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24. The stock has a market cap of $345.90, a P/E ratio of -4.17 and a beta of 1.38.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/03/21/aveo-pharmaceuticals-aveo-given-news-impact-score-of-0-22/1923606.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.